This suggests that F. tularensis may possess specific factors that aid in evasion of these innate immune defenses. We carried out a microarray-based, negative-selection screen in an intranasal model of
Francisella novicida infection to identify Francisella genes that buy MK-1775 contribute to bacterial growth specifically in the lungs of mice. Genes in the bacterial tryptophan biosynthetic pathway were identified as being important for F. novicida growth specifically in the lungs. In addition, a host tryptophan-catabolizing enzyme, indoleamine 2,3-dioxygenase 1 (IDO1), is induced specifically in the lungs of mice infected with F. novicida or Streptococcus pneumoniae. Furthermore, the attenuation of F. novicida tryptophan mutant bacteria was rescued in Selleckchem PD-1/PD-L1 Inhibitor 3 the lungs of IDO1(-/-) mice. IDO1 is a lung-specific innate immune mechanism that controls pulmonary Francisella infections.”
“OBJECTIVE: This subgroup analysis of a phase-3 study evaluated the efficacy and safety of oxybutynin chloride topical gel (OTG) in women with overactive bladder syndrome (OAB).\n\nSTUDY DESIGN: Women (n = 704) with urgency-predominant urinary incontinence received OTG or placebo for 12 weeks. The primary end-point was change from baseline to last observation in number of daily incontinence
episodes. Treatments were compared with the use of analysis of covariance.\n\nRESULTS: OTG significantly reduced the number (mean +/- standard deviation) of daily incontinence episodes (OTG, -3.0 +/- 2.8 episodes; placebo, -2.5 +/- 3.0 episodes; P < .0001), reduced urinary frequency (P = .0013), increased voided volume (P = .0006), and improved select health-related quality-of-life domains (P <= .0161) vs placebo. Dry mouth was the only drug-related adverse event significantly more common with OTG (7.4%) than with placebo (2.8%; P = .0062).\n\nCONCLUSION: OTG was well tolerated and provided significant improvement in urinary symptoms and health-related quality of life in women with OAB.”
“We hypothesized that chlorophyllin (CHLN) would reduce benzo[a]pyrene-DNA (BP-DNA) adduct levels.
Using normal human mammary epithelial cells (NHMECs) exposed to 4 mu M BP for 24 hr in the presence or absence of 5 mu M CHLN, we measured BP-DNA adducts by chemiluminescence immunoassay (CIA). The protocol included selleck compound the following experimental groups: BP alone, BP given simultaneously with CHLN (BP+CHLN) for 24 hr, CHLN given for 24 hr followed by BP for 24 hr (preCHLN, postBP), and CHLN given for 48 hr with BP added for the last 24 hr (preCHLN, postBP+CHLN). Incubation with CHLN decreased BPdG levels in all groups, with 87% inhibition in the preCHLN, postBP+CHLN group. To examine metabolic mechanisms, we monitored expression by Affymetrix microarray (U133A), and found BP-induced up-regulation of CYP1A1 and CYP1B1 expression, as well as upregulation of groups of interferon-inducible, inflammation and signal transduction genes.